Diminuição da expressão dos receptores de melatonina MT1 e MT2 em áreas especificas do sistema nervoso central de roedores submetidos a um tratamento crônico com Reserpina

• Ano de defesa: 2017
• Autor(a) principal: Silva, Kayo Diógenes de Azevedo
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Brasil; UFRN; PROGRAMA DE PÓS-GRADUAÇÃO EM PSICOBIOLOGIA
• Palavras-chave em Português: Doença de Parkinson; Receptores de melatonina; NE; VLPO; SN; ZSPV; CNPQ::CIENCIAS BIOLOGICAS: PSICOBIOLOGIA
• Link de acesso: https://repositorio.ufrn.br/jspui/handle/123456789/24445

Parkinson's disease (PD) is a neurodegenerative disorder that mainly affects males with advancing age. PD is characterized by several motor symptoms such as tremors, bradykinesia, stiffness and postural changes. In addition to these, cognitive symptoms such as attention and memory deficits, dementia and mood changes are also present. It is also possible to notice a marked change in the sleep architecture of patients with PD. The hormone melatonin synthesized mainly by the pineal gland located in the thalamus is considered one of the hormones that induce the sleep phase of the organisms. Its action occurs after binding to specific receptors, MT1 and MT2. In the present study, 15 male Wistar rats (10 months) were divided into two groups called Control (CTR) and Reserpine (RES). These animals were submitted to a chronic protocol of 20 injections of reserpine, in order to create symptoms similar to PD. During the experimental protocol the animals were evaluated by catalepsy test. At the end of the treatment the animals were sacrificed and submitted to an immunohistochemical procedure to identify the MT1 and MT2 receptors in 5 areas of the central nervous system related directly to the sleep cycle and with more evident symptoms of PD, VLPO, SN and ZSPV. Our results showed that during the period of treatment the animals of the reserpine group presented a considerable and progressive motor deficit that were accentuated on days seven, eight, nine and ten of injections. Our immunohistochemical analyzes have shown that there is a significant reduction in the expression of melatonin receptors in the reserpine animals in all evaluated nuclei, however, new studies are necessary to better understand the real reason for this decrease in receptor expression and whether this decrease has a significant effect on Observed in patients with PD.